Immunicum is developing an off-the-shelf dendritic cell therapy that was evaluated in a midstage trial involving 70 patients with kidney tumors, 45 of whom received the cancer immunotherapy. Results indicated 5 of the 45 patients treated with the immunotherapy and 1 of the 25 patients in the control group showed no further evidence of disease.
Swedish biotech tests off-the-shelf immunotherapy for kidney tumors
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.